0001144204-19-014887.txt : 20190319
0001144204-19-014887.hdr.sgml : 20190319
20190319170422
ACCESSION NUMBER: 0001144204-19-014887
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190318
FILED AS OF DATE: 20190319
DATE AS OF CHANGE: 20190319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oren Dan
CENTRAL INDEX KEY: 0001636701
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 19692218
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dexcel Pharma Technologies Ltd.
CENTRAL INDEX KEY: 0001720007
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 19692219
BUSINESS ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
BUSINESS PHONE: 97246364040
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 3060000
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dexxon Holdings Ltd.
CENTRAL INDEX KEY: 0001636684
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 19692220
BUSINESS ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
BUSINESS PHONE: 972-4-636404
MAIL ADDRESS:
STREET 1: 1 DEXCEL STREET
CITY: OR AKIVA
STATE: L3
ZIP: 30600000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Sciences Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
tv516472_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-03-18
0
0001636050
Axovant Sciences Ltd.
AXON
0001636684
Dexxon Holdings Ltd.
1 DEXCEL STREET
OR AKIVA
L3
3060000
ISRAEL
0
0
1
0
0001720007
Dexcel Pharma Technologies Ltd.
1 DEXCEL STREET
OR AKIVA
L3
3060000
ISRAEL
0
0
1
0
0001636701
Oren Dan
1 DEXCEL STREET
OR AKIVA
L3
3060000
ISRAEL
0
0
1
0
Common Shares, $0.00001 par value per share
2019-03-18
4
P
0
6666667
1.50
A
105952381
I
See footnotes
Dexxon Holdings Ltd. ("Dexxon"), Dexcel Pharma Technologies Ltd. ("DPT") and Dan Oren (together with Dexxon and DPT the "Reporting Persons") are filing this Form 4 because they may be deemed to have dispositive power and, therefore, beneficial ownership, over the common shares (the "Common Shares") of Axovant Sciences Ltd. held by Roivant Sciences Ltd. ("Roivant"). Roivant's bye-laws provide Dexxon and DPT, voting unanimously with three other major shareholders of Roivant, with the right to override certain decisions of Roivant's board of directors, including with respect to dispositions of the Common Shares.
Voting and dispositive decisions of Dexxon are made by its sole director, Dan Oren. Voting and dispositive decisions of DPT are made by its President and Chief Executive Officer, Dan Oren. Dan Oren is ultimately the sole shareholder of each of Dexxon and DPT. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by Roivant. The Reporting Persons do not directly own any Common Shares. The Reporting Persons disclaim beneficial ownership of the Common Shares owned by Roivant, except to the extent of their pecuniary interest therein. The filing of this statement shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise.
/s/ Dexxon Holdings Ltd. by Dan Oren, Director
2019-03-19
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, President & CEO
2019-03-19
/s/ Dan Oren
2019-03-19